JINXIN TECHNOLOGY HOLDIN-ADR (NAMI) Fundamental Analysis & Valuation

NASDAQ:NAMI • US47760D1028

0.4847 USD
0 (-0.31%)
Last: Mar 6, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NAMI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

NAMI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 75 industry peers in the Diversified Consumer Services industry. While NAMI has a great health rating, its profitability is only average at the moment. NAMI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. NAMI Profitability Analysis

1.1 Basic Checks

  • In the past year NAMI was profitable.
NAMI Yearly Net Income VS EBIT VS OCF VS FCFNAMI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 20M -20M 40M 60M 80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 8.30%, NAMI is in the better half of the industry, outperforming 77.33% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 16.95%, NAMI is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 13.77%, NAMI belongs to the top of the industry, outperforming 86.67% of the companies in the same industry.
  • NAMI had an Average Return On Invested Capital over the past 3 years of 46.99%. This is significantly above the industry average of 11.21%.
  • The 3 year average ROIC (46.99%) for NAMI is well above the current ROIC(13.77%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 8.3%
ROE 16.95%
ROIC 13.77%
ROA(3y)30.62%
ROA(5y)N/A
ROE(3y)91.51%
ROE(5y)N/A
ROIC(3y)46.99%
ROIC(5y)N/A
NAMI Yearly ROA, ROE, ROICNAMI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 50 100 150

1.3 Margins

  • Looking at the Profit Margin, with a value of 4.99%, NAMI is in the better half of the industry, outperforming 62.67% of the companies in the same industry.
  • With a decent Operating Margin value of 6.67%, NAMI is doing good in the industry, outperforming 61.33% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 28.78%, NAMI is doing worse than 65.33% of the companies in the same industry.
Industry RankSector Rank
OM 6.67%
PM (TTM) 4.99%
GM 28.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NAMI Yearly Profit, Operating, Gross MarginsNAMI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NAMI Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NAMI is creating value.
  • The number of shares outstanding for NAMI has been reduced compared to 1 year ago.
  • There is no outstanding debt for NAMI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NAMI Yearly Shares OutstandingNAMI Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M
NAMI Yearly Total Debt VS Total AssetsNAMI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • NAMI has an Altman-Z score of 2.52. This is not the best score and indicates that NAMI is in the grey zone with still only limited risk for bankruptcy at the moment.
  • NAMI has a Altman-Z score of 2.52. This is in the better half of the industry: NAMI outperforms 66.67% of its industry peers.
  • There is no outstanding debt for NAMI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.52
ROIC/WACC1.83
WACC7.54%
NAMI Yearly LT Debt VS Equity VS FCFNAMI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 1.67 indicates that NAMI should not have too much problems paying its short term obligations.
  • With a decent Current ratio value of 1.67, NAMI is doing good in the industry, outperforming 72.00% of the companies in the same industry.
  • A Quick Ratio of 1.62 indicates that NAMI should not have too much problems paying its short term obligations.
  • NAMI has a Quick ratio of 1.62. This is in the better half of the industry: NAMI outperforms 72.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.62
NAMI Yearly Current Assets VS Current LiabilitesNAMI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. NAMI Growth Analysis

3.1 Past

  • NAMI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.15%.
  • NAMI shows a small growth in Revenue. In the last year, the Revenue has grown by 7.00%.
EPS 1Y (TTM)-35.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NAMI Yearly Revenue VS EstimatesNAMI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 100M 200M 300M 400M

More info and screens

Find the best growth stocksShow best growing peers

3

4. NAMI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 4.85, which indicates a rather cheap valuation of NAMI.
  • Based on the Price/Earnings ratio, NAMI is valued cheaper than 96.00% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.29, NAMI is valued rather cheaply.
Industry RankSector Rank
PE 4.85
Fwd PE N/A
NAMI Price Earnings VS Forward Price EarningsNAMI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • NAMI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NAMI is cheaper than 93.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.9
NAMI Per share dataNAMI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NAMI Dividend Analysis

5.1 Amount

  • No dividends for NAMI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NAMI Fundamentals: All Metrics, Ratios and Statistics

JINXIN TECHNOLOGY HOLDIN-ADR

NASDAQ:NAMI (3/6/2026, 8:00:02 PM)

0.4847

0 (-0.31%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)12-22
Earnings (Next)04-13
Inst Owners0.16%
Inst Owner Change-97.85%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap33.14M
Revenue(TTM)406.40M
Net Income(TTM)20.27M
AnalystsN/A
Price TargetN/A
Short Float %0.02%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 4.85
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF N/A
P/B 1.91
P/tB 4.35
EV/EBITDA 2.9
EPS(TTM)0.1
EY20.63%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.86
BVpS0.25
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.76
Profitability
Industry RankSector Rank
ROA 8.3%
ROE 16.95%
ROCE 17.43%
ROIC 13.77%
ROICexc 17.55%
ROICexgc 38.89%
OM 6.67%
PM (TTM) 4.99%
GM 28.78%
FCFM N/A
ROA(3y)30.62%
ROA(5y)N/A
ROE(3y)91.51%
ROE(5y)N/A
ROIC(3y)46.99%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)59.48%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.66
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.67
Quick Ratio 1.62
Altman-Z 2.52
F-ScoreN/A
WACC7.54%
ROIC/WACC1.83
Cap/Depr(3y)131.41%
Cap/Depr(5y)N/A
Cap/Sales(3y)7.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-66.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-182%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.56%
OCF growth 3YN/A
OCF growth 5YN/A

JINXIN TECHNOLOGY HOLDIN-ADR / NAMI FAQ

Can you provide the ChartMill fundamental rating for JINXIN TECHNOLOGY HOLDIN-ADR?

ChartMill assigns a fundamental rating of 4 / 10 to NAMI.


What is the valuation status for NAMI stock?

ChartMill assigns a valuation rating of 3 / 10 to JINXIN TECHNOLOGY HOLDIN-ADR (NAMI). This can be considered as Overvalued.


What is the profitability of NAMI stock?

JINXIN TECHNOLOGY HOLDIN-ADR (NAMI) has a profitability rating of 4 / 10.


What is the financial health of JINXIN TECHNOLOGY HOLDIN-ADR (NAMI) stock?

The financial health rating of JINXIN TECHNOLOGY HOLDIN-ADR (NAMI) is 7 / 10.